Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.

It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.

The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial.

Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial.

Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.